Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin CT J Price, D Zannino, K Wilson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancerM E R O'Brien, N Wigler, M Inbar, et al.
The New England Journal of Medicine|September 28, 2000
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupL B Saltz, J V Cox, C Blanke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM studyG Folprecht, C Pericay, M P Saunders, et al.
British Journal of Cancer|December 3, 2011
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancerD Goldstein, N Spry, M M Cummins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
Pageof 4